JCI The Journal of Clinical Investigation

Clinical and immunologic features in severe and moderate Coronavirus Disease 2019

Guang Chen, ..., Jianping Zhao, Qin Ning

J Clin Invest. 2020. https://doi.org/10.1172/JCI137244.

Clinical Medicine In-Press Preview COVID-19 Immunology Infectious disease

BACKGROUND. Since December 2019, an outbreak of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and is now becoming a global threat. We aimed to delineate and compare the immunologic features of severe and moderate COVID-19.

METHODS. In this retrospective study, the clinical and immunologic characteristics of 21 patients (17 male and 4 female) with COVID-19 were analyzed. These patients were classified as severe (11 cases) and moderate (10 cases) according to the Guidelines released by the National Health Commission of China.

RESULTS. The median age of severe and moderate cases was 61.0 and 52.0 years, respectively. Common clinical manifestations included fever, cough and fatigue. Compared to moderate cases, severe cases more frequently had dyspnea, lymphopenia, and hypoalbuminemia, with higher levels of alanine aminotransferase, lactate dehydrogenase, C-reactive protein, ferritin and D-dimer as well as markedly higher levels of IL-2R, IL-6, IL-10, and TNF- α . Absolute number of T lymphocytes, CD4⁺T and CD8⁺T cells decreased in nearly all the patients, and were markedly lower in severe cases (294.0, 177.5 and 89.0 × 10⁶/L) than moderate cases (640.5, 381.5 and 254.0 × 10⁶/L). The expressions [...]



Find the latest version:

https://jci.me/137244/pdf

Clinical and immunologic features in severe and moderate Coronavirus Disease 2019 1 Guang Chen^{1*}, Di Wu^{1*}, Wei Guo^{1*}, Yong Cao^{2*}, Da Huang^{1†}, Hongwu Wang^{1†}, Tao Wang^{2†}, 2 Xiaoyun Zhang^{1†}, Huilong Chen¹, Haijing Yu¹, Xiaoping Zhang¹, Minxia Zhang³, Shiji Wu³, 3 Jianxin Song¹, Tao Chen¹, Meifang Han¹, Shusheng Li⁴, Xiaoping Luo⁵, Jianping Zhao², Qin 4 Ning¹ 5 6 7 ¹Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, 8 Huazhong University of Science and Technology, Wuhan, China 9 ²Department of Respiratory Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 10 ³Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong 11 12 University of Science and Technology, Wuhan, China ⁴Department of Emergency Medicine, Tongji Hospital, Huazhong University of Science and 13 Technology, Wuhan, China 14 ⁵Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of 15 16 Science and Technology, Wuhan, China 17 Authorship note: GC, DW, WG and YC share first authorship; DH, HW, TW and XZ are co-18 19 second authors 20 Address correspondence to: Qin Ning, Department and Institute of Infectious Disease, Tongji 21 Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Avenue, Wuhan 430030, China. Phone: 86.27.8366.2391; Email: gning@vip.sina.com. 22 Or to Di Wu, Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical 23 24 College, Huazhong University of Science and Technology, No. 1095, Jiefang Avenue, Wuhan 25 430030, China. Phone: 86.27.8366.2391; Email: woody 1984@163.com. Conflict of interest: The authors have declared that no conflict of interest exists. 26 27

28 Abstract

Background: Since December 2019, an outbreak of Coronavirus Disease 2019 (COVID-19)
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan,
and is now becoming a global threat. We aimed to delineate and compare the immunologic
features of severe and moderate COVID-19.

33 Methods: In this retrospective study, the clinical and immunologic characteristics of 21 patients

34 (17 male and 4 female) with COVID-19 were analyzed. These patients were classified as severe

(11 cases) and moderate (10 cases) according to the Guidelines released by the National Health
 Commission of China.

37 Results: The median age of severe and moderate cases was 61.0 and 52.0 years, respectively. Common clinical manifestations included fever, cough and fatigue. Compared to moderate 38 cases, severe cases more frequently had dyspnea, lymphopenia, and hypoalbuminemia, with 39 higher levels of alanine aminotransferase, lactate dehydrogenase, C-reactive protein, ferritin 40 41 and D-dimer as well as markedly higher levels of IL-2R, IL-6, IL-10 and TNF-a. Absolute 42 number of T lymphocytes, CD4⁺T and CD8⁺T cells decreased in nearly all the patients, and 43 were markedly lower in severe cases (294.0, 177.5 and $89.0 \times 10^{6}/L$) than moderate cases (640.5, 381.5 and 254.0 \times 10⁶/L). The expressions of IFN- γ by CD4⁺T cells tended to be lower 44 in severe cases (14.1%) than moderate cases (22.8%). 45

46 Conclusion: The SARS-CoV-2 infection may affect primarily T lymphocytes particularly
47 CD4⁺T and CD8⁺ T cells, resulting in decrease in numbers as well as IFN-γ production. These
48 potential immunological markers may be of importance due to their correlation with disease

49 severity in COVID-19.

50 **Trial registration:** This is a retrospective observational study without a trial registration 51 number.

Funding: This work is funded by grants from Tongji Hospital for Pilot Scheme Project, and partly supported by the Chinese National Thirteenth Five Years Project in Science and Technology for Infectious Disease (2017ZX10202201).

Role of funding source: The funding listed above supports the studies of infectious disease,
including the emerging infectious disease.

57 Keywords: SARS-CoV-2; COVID-19; cytokines; lymphocytes; pneumonia

59 Introduction

Coronaviruses (CoV) are a large family of respiratory viruses that can cause diseases ranging 60 61 from the common cold to the Middle-East Respiratory Syndrome (MERS) and the Severe Acute Respiratory Syndrome (SARS) (1, 2), both of which are zoonotic in origin and induce fatal 62 63 lower respiratory tract infection as well as extrapulmonary manifestations. The new coronavirus, officially designated as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is 64 a member of Beta-CoV lineage B, which was first identified in Wuhan by the Chinese Center 65 66 for Disease Control and Prevention (CDC) (3, 4). Recent reports have provided evidence for person to person transmission of the SARS-CoV-2 in family and hospital settings (5, 6). As of 67 February 27, 2020, the number of SARS-CoV-2 cases globally had eclipsed 82567, largely 68 exceeding the total number of SARS cases during the 2003 epidemic, and more than 2810 69 people had now died. The outbreak of SARS-CoV-2-induced Coronavirus Disease 2019 70 71 (COVID-19) has put health authorities on high alert in China and across the globe.

72 It has been revealed that SARS-CoV-2 has a genome sequence 75% to 80% identical to the 73 SARS-CoV and has more similarities to several bat coronaviruses (7). Both clinical and epidemiological features of patients with COVID-19 have recently been reported, 74 demonstrating that the SARS-CoV-2 infection can cause clusters of severe respiratory illness 75 with clinical presentations greatly resembling SARS-CoV, leading to intensive care unit (ICU) 76 77 admission and high mortality (8). Clinical manifestations have included fever, fatigue, dry 78 cough, shortness of breath, and acute respiratory distress syndrome. Additionally, a study of the first 41 laboratory-confirmed cases with COVID-19 showed that 63% of patients had 79 80 lymphopenia, and cytokine storm could be associated with disease severity. However, information on immunologic features between severe and moderate COVID-19 is scarce (8). 81

In this study, we performed a comprehensive evaluation of characteristics of 21 patients with COVID-19 admitted to Tongji Hospital, Wuhan. We aimed to compare the clinical and immunologic features between severe cases and moderate cases. These findings may help us extend our understanding of the risk factors associated with disease severity in the SARS-CoV-2 infection.

87 Results

88 Patient demographics and baseline characteristics of severe and moderate COVID-19

89 As of January 27, 2020, a total of 21 admitted hospital patients with pneumonia were identified 90 as laboratory-confirmed SARS-CoV-2 infection at Wuhan Tongji hospital. Of these patients, only four patients including a familial cluster of three confirmed cases had direct exposure to 91 Huanan seafood market. According to the Guidelines for diagnosis and management of 92 COVID-19 (6th edition, in Chinese) issued by the National Health Commission of China (9), 11 93 94 (52.4%) patients with percutaneous oxygen saturation (SpO2) \leq 93% or respiratory rates \geq 30 per 95 min on room air who required high-flow nasal cannula or non-invasive mechanical ventilation 96 using the Bilevel Positive Airway Pressure (BiPAP) mode to correct hypoxemia, were classified as having severe COVID-19, whereas 10 (47.6%) patients not reaching criteria of severe 97 COVID-19 were considered as moderate. There were more male patients in both severe cases 98 99 and moderate cases. The median age of the severe cases (61.0 years) was significantly older 100 than moderate cases (52.0 years) (Table 1). More severe cases had comorbidity. The median 101 time from onset of symptoms to first hospital admission was 8.0 days in severe cases and 7.0 102 days in moderate cases.

103Four of eleven severe cases died at an average of 20 days after the onset of the illness. Of these104four deceased patients, all of them were male and aged 50 years and older, with two cases105having hypertension. Median age of deceased cases was 64.0 years old. Three of the deceased106cases had arterial oxygen tension (PaO2) over inspiratory oxygen fraction (FiO2) (PaO2/FiO2)107ratio \leq 100 on admission.

108 Excluding one patient without a clear history due to the disorder of consciousness (coma) 109 (classified as severe case), the most common clinical manifestations at onset of illness include 110 fever, cough, fatigue and myalgia. Less common symptoms include sputum production, 111 diarrhea, headache and hemoptysis. Compared to moderate cases, chest tightness tended to be more common in severe cases. In addition, tachypnea and dyspnea were only developed in 112 113 severe cases. All the severe cases developed dyspnea, and nine of them with SpO2 <93% 114 showed no improved SpO2 even with high-flow nasal cannula, who were then ventilated using the BiPAP mode to treat hypoxemia. Arterial blood gas (ABG) test was performed in 10 patients 115

116 on admission (six severe and four moderate cases). Of them, PaO2/FiO2 ratio was significantly

- lower in severe cases (104.8) than moderate cases (371.7), with 3 out of 6 severe patients below
 100.
- 119

120 Laboratory findings and CT scans of severe and moderate COVID-19

121 Compared with normal range, the whole blood count on admission of three (30%) moderate cases showed mild leucopenia, while white blood cell (WBC) counts were normal or slightly 122 123 increased above the upper limit of normal (ULN) in all the severe cases (Table 2). Both WBC 124 and neutrophil counts were significantly higher in severe cases than moderate cases. Whereas lymphocyte counts were significantly lower in severe cases $(0.7 \times 10^9/L)$ than moderate cases 125 $(1.1 \times 10^{9}/L)$. Lymphopenia (lymphocyte count $<0.8 \times 10^{9}/L$) was developed in 8 (72.7%) 126 severe cases and only 1 (10.0%) moderate cases (p=0.008). Overall, severe cases have increased 127 WBC count (p = 0.003), but lower lymphocyte count (p = 0.049). 128

129 Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were 130 significantly higher in severe cases than moderate cases. Albumin concentrations were 131 significantly lower in severe cases than moderate cases, and hypoalbuminemia (albumin<32g/L) was more frequent in severe cases (Table 2). Levels of lactate dehydrogenase (LDH), 132 concentrations of serum high-sensitivity C-reactive protein (hsCRP), ferritin and D-dimer 133 134 levels were markedly higher in severe cases than moderate cases. Besides, serum levels of procalcitonin tended to be higher in severe cases than in moderate cases. These results suggest 135 136 an increased level of systemic inflammation in severe cases.

137 Interstitial lung abnormalities were observed in chest computed tomography (CT) scans of all patients on admission. Of the 21 patients, 10 (90.9%) severe cases and 7 (70%) moderate cases 138 139 had bilateral involvement on admission (Table 2). The typical findings of chest CT images of 140 severe COVID-19 on admission showed bilateral ground glass opacity and subsegmental areas of consolidation (Figure 1A), then progressed rapidly with mass shadows of high density in 141 both lungs (Figure 1B). Whereas the representative chest CT images of moderate COVID-19 142 143 showed bilateral ground glass opacity (Figure 1C). Later chest CT images revealed bilateral 144 ground-glass opacity had been resolved (Figure 1D).

145

146 Immunologic features of severe and moderate COVID-19

147 We detected the plasma cytokine levels to examine the presence of cytokine storm in these patients. Evaluation of serum cytokines on admission revealed that levels of interleukin (IL)-148 2R, IL-6, IL-10, and tumor necrosis factor- α (TNF- α) were markedly higher in severe cases 149 than in moderate cases (Figure 2, Supplementary Table 1). IL-1ß concentrations were 150 151 undetectable (<5pg/mL) in nearly all the patients with either severe or moderate COVID-19. 152 Overall, we found that macrophage-related proinflammatory cytokines, particularly IL-6, IL-10 and TNF- α , are significantly increased in majority of severe cases. Of note, IL-6 levels were 153 154 increased in both moderate and severe cases.

We next examined the proportions and effector functions of immune cells in peripheral blood 155 156 (Figure 3, Table 3). Preliminary analysis of circulating immune cells subsets as shown in Table 157 3 demonstrated that absolute numbers of total T lymphocytes, CD4⁺T cells and CD8⁺T cells were reduced below the lower limit of normal (LLN) in the vast majority of patients with either 158 severe or moderate COVID-19, and they were reduced more profoundly in severe cases (294.0, 159 160 177.5 and 89.0×10^{6} /L) than in moderate cases (640.5, 381.5 and 254.0 × 10⁶/L) (Figure 3A, 161 3B). The proportion of B cells was significantly higher in severe cases (20.2%) than in moderate cases (10.8%). This could be partly due to the more significant decrease of T lymphocytes in 162 163 severe cases. In addition, six (75.0%) of eight severe cases showed a broad, significant decrease in all the lymphocyte subsets excluding B cells, with total T lymphocytes counts below $400 \times$ 164 10^{6} /L, CD8⁺T cells counts below 150×10^{6} /L, and NK cells counts below 77×10^{6} /L. Of these 165 166 six patients, three (50%) eventually died.

167 Moreover, the frequencies of regulatory T cells (Tregs) (CD4⁺CD25⁺CD127^{low+}) and 168 CD45RA⁺Tregs were reduced (below LLN) in nearly all the severe and moderate cases, with 169 CD45RA⁺Tregs proportion was markedly lower in severe cases (0.5%) than in moderate cases 170 (1.1%). The reduced expressions of interferon- γ (IFN- γ) by CD4⁺T, CD8⁺T and NK cells below 171 LLN were observed in some patients with severe (50%, 16.7% and 16.7%) or moderate 172 COVID-19 (14.3%, 0% and 14.3%). The expressions of IFN- γ by CD4⁺T cells tended to be 173 lower in severe cases (14.1%) than moderate cases (22.8%) (Table 3, Figure 2C). However,

- 174 there was no significant difference in terms of mean fluorescence intensity of IFN-γ production
- 175 by CD4⁺T, CD8⁺T or NK cells (data not shown). Overall, we found a significant reduction in
- 176 $CD4^+$ T cell count and a borderline reduction in IFN- γ expression in severe cases.
- 177

178 Complications and clinical outcomes of COVID-19

With regards to complications as shown in Supplementary Table 2, common complications observed in severe cases included acute respiratory distress syndrome (100.0% of patients with available ABG data), respiratory failure (83.3%). Less common complications among the severe cases included secondary infection (27.3%), acute cardiac injury (9.1%), and hypoxic encephalopathy (18.2%), acute kidney injury (18.2%), shock (9.1%) and acute liver injury (9.1%), most of which were not developed in any recovered cases.

All the severe and moderate cases were given empirical antimicrobial treatment (moxifloxacin 185 and/or cephalosporin, etc.). 7 (63.6%) severe cases and all moderate cases received antiviral 186 therapy (oseltamivir and/or ganciclovir). In Addition, all severe and moderate cases were 187 administered corticosteroids (methylprednisolone) during the course of hospitalization. Nine 188 189 (81.8%) severe cases and no moderated case required non-invasive mechanical ventilation. As of February 2, 2020, 4 (36.4 %) of 11 severe cases and none (0.0 %) of the moderate cases died, 190 the median days from illness onset to death was 20 days. One severe and one moderate case 191 192 recovered. Patients were transferred to the designated hospital after being identified as having 193 laboratory-confirmed SARS-CoV-2 infection.

194 Discussion

This is the first preliminary study evaluating descriptively the immunologic characteristics of 195 196 patients with laboratory-confirmed SARS-CoV-2 infection. Both clinical and epidemiological 197 features of patients with COVID-19 have recently been reported (5, 6, 8, 10). However, there is insufficient knowledge of pathophysiological parameters particularly immunologic indicators 198 to understand the mechanism involved in COVID-19. Consistent with previous reports(8), this 199 present study showed that a male predominance in the incidence of COVID-19 has been noted 200 201 similar to that of SARS-CoV, indicating males are more susceptible to SARS-CoV-2 infection than females. Older males (>50 years old), particularly those with underlying comorbidities 202 may be more likely to develop severe COVID-19. The most common clinical manifestations at 203 onset of illness included fever, cough, fatigue and myalgia. Severe cases more frequently had 204 dyspnea and developed acute respiratory distress syndrome. In terms of laboratory findings, 205 leukocytosis ($\geq 10 \times 10^9/L$) but lymphopenia ($< 0.8 \times 10^9/L$) were more common in severe cases 206 207 than in moderate cases. ALT, LDH, D-dimer and inflammatory markers including hsCRP and 208 ferritin were significantly higher in severe cases than in moderate cases. Serum concentrations 209 of both pro-inflammatory cytokines and anti-inflammatory cytokines, including IL-2R, IL-6, TNF-α and IL-10 increased in the majority of severe cases and were markedly higher than did 210 211 those in moderate cases, suggesting cytokine storms might be associated with disease severity. 212 Similarly, SARS was also characterized by exuberant inflammatory responses and lung damage. 213 A study using mice model of SARS demonstrated that rapid kinetics of SARS-CoV replication 214 and delay in IFN-I signaling promoted inflammatory monocyte-macrophage accumulation, 215 resulting in elevated lung cytokine/chemokine levels, vascular leakage, and suboptimal T cell 216 responses (11). The underlying the cellular origin and mechanism involving cytokine 217 accumulation in COVID-19 warrants further exploration.

Additionally, we noted that SARS-CoV-2 infection can cause a significant reduction in circulating lymphocytes and T cell subsets. Although the proportions of T cells subsets in peripheral blood remained within the normal range in most patients, decreased CD4⁺T cell and CD8⁺T cell counts below LLN was considerably frequent in both severe and moderate cases. More importantly, the number of CD4⁺T cells and CD8⁺T cells was markedly lower in severe 223 cases than moderate cases. In contrast, both the proportion and number of B cells were not 224 reduced in most patients, with 75.0% of severe cases showing increased proportion of B cells. 225 This could be partly due to the more significant decrease of T lymphocytes in these patients. It 226 is notable that six out of eight severe cases and none of moderate cases with available immunologic data exhibited a broad, significant decline in all the lymphocyte subsets excluding 227 B cells. Of these six patients, three eventually died. Moreover, the production of IFN- γ by 228 CD4⁺T cells but not CD8⁺T cells or NK cells tended to be lower in severe cases than moderate 229 230 cases. These data suggest that SARS-CoV-2 infection induces lymphopenia, particularly CD4⁺T and CD8⁺T cells, as well as suppressed IFN- γ production by CD4⁺T cells, which 231 232 correlates with disease severity of COVID-19.

233 Although the total Tregs proportion was comparable between severe cases and moderate cases, 234 severe cases showed a significantly lower proportion of CD45RA⁺ naive Tregs (nTregs) and a 235 bit higher proportion of their memory counterparts CD45RO⁺ memory Tregs (mTregs). nTregs 236 might be activated in the periphery by antigen and subsequently converted to mTregs, and thus 237 is thought to represent precursor cells of antigen -experienced mTregs and possess an 238 equivalently strong suppressive capacity as compared with mTregs (12). It is reported that peripheral homeostatic mechanisms are crucial in the control of Tregs diversity and 239 concomitantly in the maintenance of immune tolerance in healthy individuals. Disturbances 240 241 within these mechanisms may have detrimental consequences and could contribute to the 242 development of certain diseases particularly autoimmune diseases (12). Whether altered Treg 243 proportion observed in this current study accounts for the severity of COVID-19, or correlates 244 to the viremia, warrants further investigation.

245 $CD4^+$ T cells play a pivotal role in regulating immune responses, orchestrating the deletion and 246 amplification of immune cells, especially $CD8^+$ T cells. $CD4^+$ T cells facilitate virus-specific 247 antibody production via the T-dependent activation of B cells (13). However, $CD8^+$ T cells exert 248 their effects mainly through two mechanisms, cytolytic activities against target cells or 249 cytokines secretion, including IFN- γ , TNF- α , and IL-2 as well as many chemokines (14). The 250 production of IFN- γ is essential for the resistance against infection of various pathogens such 251 as virus, bacteria, and parasite (15). As a major source of IFN- γ , the ability of T cells to respond to infection is part of the adaptive immune response and takes days to develop a prominent
IFN-γ response.

In this study, albeit decreased numbers of CD8⁺ T cells in severe cases, the proportion of 254 255 CD8⁺HLA-DR⁺ T cells was slightly greater than that in moderate cases, which was in agreement with a recent case report (16). Circulating CD8⁺T cells were found to harbor high 256 concentrations of cytotoxic granules, including perforin and granulysin (16). Besides, a 257 "cytokine storm" was exhibited in nearly all these populations, the only current available 258 259 histological examination of a severe case who died of SARS-CoV-2 demonstrated lung interstitial mononuclear inflammatory infiltrates, dominated by lymphocytes, and 260 261 multinucleated syncytial cells with atypical enlarged pneumocytes in the intra-alveolar spaces (16). These findings suggested that overactivation of cytotoxicity CD8⁺T cells, along with over 262 production of pro-inflammation cytokines, might account for, at least in part, the 263 immunogenicity of COVID-19. Nevertheless, the cellular source (T cells, dendritic cells or 264 265 macrophages) of these cytokines remains to be determined.

The roles of T cell responses in the context of SARS-CoV and MERS-CoV infection have been 266 267 previously studied. Likewise, patients who survived SARS-CoV and MERS-CoV infections 268 usually had better immune responses than those who did not (17). The immune system plays 269 an important role in both diseases, but it is differentially affected by the two viruses (18). A 270 study in SARS-CoV mice model has shown that depletion of CD8⁺ T cells at the time of 271 infection does not affect viral replication or clearance. However, depletion of CD4⁺ T cells leads 272 to an enhanced immune-mediated interstitial pneumonitis and delayed clearance of SARS-CoV from the lungs, demonstrating the vital role of CD4⁺ T but not CD8⁺ T cells in primary SARS-273 274 CoV infection (19). A Chinese study in SARS-CoV-infected patients has demonstrated that the 275 majority of infiltrative inflammatory cells in the pulmonary interstitium are CD8⁺ T cells that 276 play an important role in virus clearance as well as in immune-mediated injury (20). After comparing T cell-deficient mice and B cell-deficient mice, it is found that T cells are able to 277 survive and kill virus-infected cells in the MERS-CoV infected lung (21). These data highlight 278 279 the importance of T lymphocytes, CD4⁺ T cells in particular, but not B cells in controlling and 280 finetuning the pathogenesis and outcomes of SARS-CoV and MERS-CoV infection. However,

a cohort study investigating adaptive immune responses to SARS-CoV infection revealed that despite no significant correlation between the total T cell responses and disease progression, the disease severity correlates strongly with high level $CD4^+$ T cell responses but not the memory $CD8^+$ T cell response (22). It is noteworthy that the immune responses evaluated in this study were in patients who recovered fully, thus whether these responses contribute to recovery or disease progression remains unclear (22).

Hin Chu et al demonstrated that MERS-CoV but not SARS-CoV can efficiently infect T cells 287 288 from the peripheral blood and from human lymphoid organs, and induce apoptosis in T cells, 289 which involves the activation of both the extrinsic and intrinsic apoptosis pathways. This may 290 partly explain the lymphopenia observed in MERS-CoV-infected patients (23). SARS-CoV can also significantly decrease peripheral CD4⁺ and CD8⁺ T lymphocyte subsets and it was related 291 292 to the onset of illness (24). Several potential mechanisms may be involved, including the 293 development of auto-immune antibodies or immune complexes triggered by viral infection, 294 directly infecting and promoting the growth inhibition and apoptosis of hematopoietic stem and 295 progenitor cells. The use of glucocorticoids may also account for the decrease of lymphocytes 296 in some SARS patients (25). At present little is known about mechanism underlying the lymphopenia caused by SARS-CoV-2 infection. In this study we could not exclude the 297 298 possibility that some of the lymphopenia may be worsen due to the use of steroids during hospitalization. Further research is required to determine the effects of corticosteroid on 299 300 lymphocytes in the context of COVID-19.

301 Our study has some limitations. First of all, we mainly evaluated the number of T cell subsets 302 and NK cells as well as their IFN- γ production, the function of these cells, as well as the role 303 of activated macrophages and lymphocytes infiltrating pulmonary interstitium remains to be 304 elucidated. Second, this study only included a small number of patients, thus the results should 305 be interpreted with caution, and statistical non-significance may not rule out difference between 306 severe and moderate cases. Third, since data regarding the viremia profile of SARS-CoV-2 are not available, further studies are needed to investigate the correlation between the virus load 307 308 kinetics and the dynamics of cellular immune responses. Clarification of these questions will 309 allow further dissection of the complex SARS-CoV-2 pathogenesis, with potential implications

- 310 for the development of therapeutics and vaccines.
- 311 In conclusion, the SARS-CoV-2 infection induced cytokine storm and lymphopenia,
- 312 particularly decrease in CD4⁺T and CD8⁺T cells counts, as well as suppressed IFN-γ production
- 313 by CD4⁺T cells, which might be correlated with disease severity of COVID-19. Gaining a
- 314 deeper understanding of the factors that affect lymphocytes particularly T lymphocytes count
- and their association between disease severity in patients with SARS-CoV-2 infection is of
- 316 importance for clinical management of COVID-19.
- 317

318 Methods

319 Study participants

From late December 2019 to January 27, 2020, a total of 21 cases who initially presented with fever or respiratory symptoms, with pulmonary infiltrates on chest CT scans in isolation ward of Department of Infectious Disease, Tongji hospital were later confirmed to be infected with SARS-CoV-2 by the local health authority. Four cases had a history of exposure to the Huanan seafood market.

We retrospectively evaluated and analyzed the medical history, physical examination, and hematological, biochemical, radiological, microbiological and immunological evaluation results obtained from these 21 patients with COVID-19. Epidemiological, clinical, laboratory, and radiological characteristics and treatment as well as outcomes data were obtained from electronic medical records. The data collection forms were reviewed independently by two researchers.

331 Clinical classifications and complication definitions

332 According to the Guidelines for diagnosis and management of COVID-19 (6th edition, in

333 Chinese) released by National Health Commission of China (9), the clinical classifications of

334 COVID-19 are as follows:

- 335 Mild cases: The clinical symptoms are mild and no pneumonia manifestation can be found in336 imaging;
- Moderate cases: Patients have symptoms like fever and respiratory tract symptoms, etc. and
 pneumonia manifestation can be seen in imaging;
- 339 Severe cases: Meeting any of the following: Respiratory distress, respiratory rates ≥ 30
- 340 breaths/min; The SpO2 \leq 93% at a rest state; PaO2/FIO2 ratio \leq 300; Patients with > 50% lesions
- 341 progression within 24 to 48 hours in pulmonary imaging should be treated as severe cases.
- 342 Critical ill cases: Meeting any of the following: Respiratory failure occurs and mechanical
- ventilation is required; Shock occurs; Complicated with other organ failure that requiresmonitoring and treatment in ICU.
- 345 Acute respiratory distress syndrome and shock were defined according to the interim guidance
- 346 of WHO for SARS-CoV-2 (26).

347 Hypoxemia was defined as PaO2/FiO2 ratio of less than 300.

Acute kidney injury was identified and classified on the basis of the highest serum creatinine level or urine output criteria according to the kidney disease improving global outcomes classification.

Acute liver injury was defined as jaundice with a total bilirubin level of ≥ 3 mg/dl and an acute increase in alanine aminotransferase of at least five times the upper limit of the normal range and/or an increase in alkaline phosphatase of at least twice the upper limit of the normal range. Cardiac injury was diagnosed if serum levels of cardiac biomarkers (e.g. troponin I) were > the 99th percentile upper reference limit, or new abnormalities were shown in electrocardiography and echocardiography.

Secondary infection including bacteria and fungus was diagnosed if the patients had clinical symptoms or signs of nosocomial pneumonia or bacteremia, and was combined with a positive culture of a new pathogen from a respiratory tract specimen or from blood samples taken \geq 48 h after admission.

361 Laboratory measurements

362 Real-Time reverse transcription polymerase chain reaction assay for SARS-CoV-2

Respiratory specimens were collected by local CDC and then shipped to designated 363 authoritative laboratories to detect the SARS-CoV-2. The presence of SARS-CoV-2 in 364 365 respiratory specimens was detected by real-time RT-PCR methods. The primers and probe 366 target to envelope gene of CoV were used and the sequences were as follows: forward primer 5'-367 5'-TCAGAATGCCAATCTCCCCAAC-3'; primer reverse 368 AAAGGTCCACCCGATACATTGA-3'; and the probe 5'CY5-CTAGTTACACTAGCCATCCTTACTGC-3'BHQ1. Conditions for the amplifications were 369 370 50°C for 15 min, 95°C for 3 min, followed by 45 cycles of 95°C for 15 s and 60°C for 30 s.

371 Clinical laboratory measurements

Initial clinical laboratory investigation included a complete blood count, serum biochemical test (including liver and renal function, creatine kinase, lactate dehydrogenase, and electrolytes), coagulation profile, as well as immunological test (including serum cytokines, peripheral immune cells subsets and the expression of IFN- γ by immune cells). Respiratory specimens, including nasal and pharyngeal swabs, or sputum were tested to exclude evidence of other virus

377 infection, including influenza, respiratory syncytial virus, avian influenza, parainfluenza virus

and adenovirus. Routine bacterial and fungal examinations were also performed.

379 Cytokine measurement

To explore the influence of SARS-CoV-2 infection on the secretion of cytokines, cytokines including IL-1 β , IL-2R, IL-6, IL-8 (also known as CXCL8), IL-10, and TNF- α were assessed in serum samples drawn shortly after hospital admission by Chemiluminescence Immunoassay (CLIA) performed on a fully automated analyzer (Immulite 1000, DiaSorin Liaison, Italy or Cobas e602, Roche Diagnostics, Germany) for all patients according to the manufacturer's instructions. IL-1 β kit (#LKL11), IL-2R kit (#LKIP1), IL-8 kit (#LK8P1), IL-10 kit (#LKXP1), and TNF- α kit (#LKNF1) were purchased from DiaSorin (Vercelli, Italy). IL-6 kit (#05109442

387 190) was purchased from Roche Diagnostics, Germany.

388 Evaluation of peripheral blood immunological indicators

389 The proportions and numbers of NK, CD4⁺T, CD8⁺T, Treg and B cells, and the expression of 390 cell surface markers as well as IFN-y expression by CD4⁺T, CD8⁺T and NK cells were studied 391 in these patients with laboratory-confirmed SARS-CoV-2 infection. Flow cytometry antibodies 392 against human surface and intracellular molecules are commercially available. The following antibodies were used: anti-CD28 (CD28.2, PE, #555729), anti-CD8 (RPA-T8, PE-Cy7, 393 #557746), anti-CD45 (2D1, PerCP, #347464), anti-HLADR (G46-6, APC, #560744), anti-CD3 394 395 (SK7, APC-Cy7, #557832), anti-CD4 (RPA-T4, V450, #560345); anti-CD45RA (HI100, FITC, #555488), anti-CD45RO (UCHL1, PE, #5618898), anti-CD127 (HIL-7R-M21, PE-Cy7, 396 397 #560822), anti-CD45 (2D1, PerCP, #347464), anti-CD25 (M-A251, APC, #561399), anti-CD3 (SK7, APC-Cy7, #557832), anti-CD4 (RPA-T4, V450, #560345); anti-CD3 (UCHT1, FITC, 398 399 #561806), anti-CD8 (RPA-T8, PE, #555367), anti-CD56 (B159, PE-Cy7, #557747), anti-IFNγ (4S.B3, APC, #551385), anti-CD4 (RPA-T4, APC-Cy7, #557871). All reagents were 400 purchased from Becton, Dickinson, and Company (BD, Franklin Lakes, USA). All samples 401 were detected by BD FACS Canto II Flow Cytometry System and analyzed with the BD FACS 402 403 Diva Software.

404 The steps of intracellular staining for IFN- γ in immune cells were as follows, cell cultures were

405 added BD GolgiStop (BD Biosciences, #554724) and stimulated for 4 hours and then 406 resuspended in FACS buffer for flow cytometry antibody staining. Peripheral blood 407 mononuclear cells (PBMCs) were stained for surface antibody at 4°C for 30 minutes and were washed with FACS buffer followed by fixation/permeabilization (BD Cytofix/Cytoperm, 408 #554722) at 4°C for 20 minutes in the dark. Then fixed/permeabilized cells were washed twice 409 with Perm/Wash buffer (BD Biosciences, #554723), then thoroughly resuspended in 50 µL of 410 Perm/Wash buffer containing a pre-determined optimal concentration of a fluorochrome-411 412 conjugated anti-IFN-y antibody or appropriate negative control and incubated at 4°C for 30 minutes in the dark. Cells were washed twice with Perm/Wash buffer and resuspended in FACS 413 414 buffer prior to flow cytometric analysis.

415 Statistics

416 Continuous variables were expressed as median (IQR) and compared with the unpaired 2-sided 417 Student's t test; categorical variables were expressed as number (%) and compared by χ 2 test 418 or Fisher's exact test between moderate and severe case groups. A two-sided α of less than 0.05 419 was considered statistically significant. Statistical analyses were done using the SPSS (version 420 19.0).

421 Study approval

The study was performed in accordance with Good Clinical Practice and the Declaration of Helsinki principles for ethical research. The study protocol was approved by the Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (located at Wuhan, China). Written informed consent was waived due to the rapid emergence of this infectious disease.

427 **Author contributions** QN and DW designed the study and had full access to all data in the 428 study and take responsibility for the integrity of data and the accuracy of the data analysis.

429 GC and DW contributed to patient recruitment, data collection, data analysis, data interpretation,

430 literature search, and writing of the manuscript.

431 WG and YC had roles in patient recruitment, data collection, and clinical management.

432 DH, HW, TW, XZ, HC, HY, XZ, MZ, SW, JS, TC, MH, SL, XL, and JZ had roles in the patient

433 management, experiments, data collection, data analysis, and data interpretation.

- 434 All authors contributed to data acquisition, data analysis, or data interpretation, and reviewed
- 435 and approved the final version of the manuscript.
- 436 GC, DW, WG and YC share first authorship; DH, HW, TW and XZ are co-second authors; and
- 437 the order in which they are listed was determined by workload.
- 438

439 Acknowledgments

- 440 We thank all the patients and their families involved in this study, as well as numerous doctors,
- 441 nurses and civilians working together to fight against the SARS-CoV-2.

442 **References**


- Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification
 of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med.* 2003;348(20):1967-76.
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, and Fouchier RA. Isolation of a
 novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med.*2012;367(19):1814-20.
- 3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients
 with Pneumonia in China, 2019. *N Engl J Med.* 2020.
- 451 4. Gralinski LE, and Menachery VD. Return of the Coronavirus: 2019-nCoV. *Viruses.*452 2020;12(2).
- 453 5. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan,
 454 China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med.* 2020.
- 6. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia
 associated with the 2019 novel coronavirus indicating person-to-person transmission: a
 study of a family cluster. *Lancet.* 2020.
- 458 7. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
 459 associated with a new coronavirus of probable bat origin. *Nature*. 2020.
- 460 8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
 461 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020.
- 462 9. New coronavirus pneumonia prevention and control program (6th ed.) (in Chinese). 2020
 463 (<u>http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/fil</u>
 464 es/b218cfeb1bc54639af227f922bf6b817.pdf).
- 10. Nanshan Chen MZ, Xuan Dong, Jieming Qu, Fengyun Gong, Yang Han, Yang Qiu, Jingli
 Wang, Ying Liu, Yuan Wei, Jia'an Xia, Ting Yu,, and Xinxin Zhang LZ. Epidemiological and
 clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:
 a descriptive study. *Lancet.* 2020.
- Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated
 Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal
 Pneumonia in SARS-CoV-Infected Mice. *Cell Host Microbe.* 2016;19(2):181-93.
- Venken K, Hellings N, Broekmans T, Hensen K, Rummens JL, and Stinissen P. Natural naive
 CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed
 in multiple sclerosis patients: recovery of memory Treg homeostasis during disease
 progression. *J Immunol.* 2008;180(9):6411-20.
- 476 13. Xu X, and Gao X. Immunological responses against SARS-coronavirus infection in humans.
 477 *Cell Mol Immunol.* 2004;1(2):119-22.
- 478 14. Frasca L PC, Piccolella E. CD4+ T cells orchestrate both amplification and deletion of CD8+
 479 T cells. Crit Rev Immunol. 1998;18(6):569-94.
- 480 15. Taylor GA, Feng CG, and Sher A. p47 GTPases: regulators of immunity to intracellular
 481 pathogens. *Nat Rev Immunol.* 2004;4(2):100-9.
- 482 16. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19
 483 associated with acute respiratory distress syndrome. *Lancet Respir Med.* 2020.
- 484 17. Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, et al. Clinical course
 485 and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus

- 486 infection. *Ann Intern Med.* 2014;160(6):389-97.
 487 18. Ying T, Li W, and Dimitrov DS. Discovery of T-Cell Infection and Apoptosis by Middle East
 488 Respiratory Syndrome Coronavirus. *J Infect Dis.* 2016;213(6):877-9.
- 489 19. Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR, et al. Cellular immune
 490 responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in
 491 senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J
 492 *Virol.* 2010;84(3):1289-301.
- Zhao JM, Zhou GD, Sun YL, Wang SS, Yang JF, Meng EH, et al. [Clinical pathology and pathogenesis of severe acute respiratory syndrome]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi.* 2003;17(3):217-21.
- Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J, et al. Rapid generation
 of a mouse model for Middle East respiratory syndrome. *Proc Natl Acad Sci U S A.*2014;111(13):4970-5.
- Li CK, Wu H, Yan H, Ma S, Wang L, Zhang M, et al. T cell responses to whole SARS
 coronavirus in humans. *J Immunol.* 2008;181(8):5490-500.
- 501 23. Chu H, Zhou J, Wong BH, Li C, Chan JF, Cheng ZS, et al. Middle East Respiratory Syndrome
 502 Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic
 503 and Intrinsic Apoptosis Pathways. *J Infect Dis.* 2016;213(6):904-14.
- He Z ZC, Dong Q, Zhuang H, Song S, Peng G, Dwyer DE. Effects of severe acute respiratory
 syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their
 subsets. *Int J Infect Dis.* 2005;9(6):323-30.
- 50725.Yang M, Li CK, Li K, Hon KL, Ng MH, Chan PK, et al. Hematological findings in SARS508patients and possible mechanisms (review). *Int J Mol Med.* 2004;14(2):311-5.
- 50926.WHO. Clinical management of severe acute respiratory infection when Novel coronavirus510(nCoV) infection is suspected: interim guidance. Jan 11, 2020.511https://www.who.int/publications-detail/clinical-management-of-severe-acute-
- 512respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. (accessed513Jan 20, 2020).
- 514
- 515

516 Figure legends

517 Figure 1: Computed tomography of the chest of patients with COVID-19


- 518 Chest CT axial view lung window from a 62-year-old female with severe COVID-19 showing
- 519 bilateral ground-glass opacity and subsegmental areas of consolidation on day 6 after symptom
- 520 onset (A), and typical presentation of a "white lung" appearance with bilateral multiple lobular
- 521 and subsegmental areas of consolidation on day 8 after symptom onset (B). Chest CT axial
- 522 view lung window from a 32-year-old male with moderate COVID-19 showing bilateral
- 523 ground-glass opacity on day 7 after symptom onset (C), and resolved bilateral ground-glass
- 524 opacity on day 11 after symptom onset (D).



527 Figure 2: Plasma cytokines levels in patients with COVID-19

528 Series of comparisons of plasma cytokines levels between severe cases (n=9) and moderate


- 529 cases (n=7). All data represent mean \pm SEM. Differences were tested using unpaired 2-sided
- 530 Student's t test.



533 Figure 3: Number of immune cell subsets and proportion of IFN-γ expression in patients

534 with COVID-19

- 535 (A) Flow cytometry staining of natural killer (NK) cells, CD4⁺T cells, CD8⁺T cells and Tregs
- as well as production of IFN- γ by CD4⁺T cells, CD8⁺T cells and NK cells from a representative
- 537 patient.
- 538 (B) A series of comparisons of absolute number of total T&B lymphocytes, CD4⁺T cells, CD8⁺T
- 539 cells and NK cells between severe cases (n=8) and moderate cases (n=6). All data represent
- 540 mean \pm SEM. Differences were tested using unpaired 2-sided Student's t test.
- 541 (C) A series of comparisons of production of IFN-γ by CD4⁺T cells, CD8⁺T cells and NK cells
- 542 between severe cases (n=6) and moderate cases (n=7). All data represent mean \pm SEM.
- 543 Differences were tested using unpaired 2-sided Student's t test.



	All patients	severe cases	moderate cases	P valu			
	(n=21)	(n=11)	(n=10)				
Characteristics							
Males, n (%)	17 (81.0%)	10 (90.9%)	7 (70.0%)	0.31			
Age, yrs	56.0 (50.0-65.0)	61.0 (56.5-66.0)	52.0 (42.8-56.0)	0.043			
>50	15 (71.4%)	10 (90.9%)	5 (50.0%)	0.043			
Huanan seafood market exposure,	4 (19.0%)	1 (9.1%)	3 (30.0%)	0.31			
n (%)							
Any comorbidity, n (%)	7 (33.3%)	5 (45.5%)	2 (20.0%)	0.36			
Hypertension, n (%)	5 (23.8%)	4 (36.4%)	1 (10.0%)	0.31			
Diabetes, n (%)	3 (14.3%)	2 (18.2%)	1 (10.0%)	1.00			
Signs and symptoms							
Fever, n/N (%)	20/20 (100%)	10/10 (100%)	10/10 (100%)	NA			
Highest temperature, °C	38.7 (38.5-39.1)	38.6 (38.4-39.3)	38.8 (38.6-39.0)	0.87			
38.1-39.0 °C, n/N (%)	12/19 (63.2%)	5/9 (55.6%)	7/10 (70.0%)	0.52			
>39.0 °C, n/N (%)	7/19 (36.8%)	4/9 (44.4%)	3/10 (30.0%)				
Cough, n/N (%)	16/20 (80.0%)	7/10 (70.0%)	9/10 (90.0%)	0.58			
Fatigue, n/N (%)	17/20 (85.0%)	10/10 (100.0%)	7/10 (70.0%)	0.21			
Myalgia, n/N (%)	8/20 (40.0%)	5/10 (50.0%)	3/10 (30.0%)	0.65			
Sputum production, n/N (%)	5/20 (25%)	2/10 (20.0%)	3/10 (30.0%)	1.00			
Headache, n/N (%)	2/20 (10.0%)	1/10 (10.0%)	1/10 (10.0%)	1.00			
Diarrhea, n/N (%)	4/20 (20.0%)	1/10 (10.0%)	3/10 (30.0%)	0.58			
Chest tightness, n/N (%)	11/20 (55.0%)	8/10 (80.0%)	3/10 (30.0%)	0.07			
Coma, n (%)	1 (4.8%)	1 (9.1%)	0 (0.0%)	1.00			
Dyspnea, n (%)	11 (52.4%)	11 (100.0%)	0 (0.0%)	0.000			
Days from illness onset to dyspnea	8.0 (7.0-10.0)	8.0 (7.0-10.0)	NA	NA			
Systolic pressure, mm Hg	122.0 (109.0-	124.0 (118.5-	120.0 (107.5-	0.17			
	135.0)	145.5)	134.0)				
>140mmHg, n (%)	4 (19.0%)	4 (36.4%)	0 (0.0%)	0.09			
Heart rate, bpm	89.0 (78.0-	95.0 (77.0-108.0)	89.0 (85.5-96.0)	0.90			
, - r	106.0)						
Respiratory rate, per min	21.0 (20.0-25.0)	25.0 (22.5-31.0)	20.0 (20.0-20.8)	0.005			
≥30, n (%)	5 (23.8%)	5 (45.5%)	0 (0.0%)	0.035			
Percutaneous oxygen saturation	11 (52.4%)	11 (100.0%)	0 (0.0%)	0.000			
≤93 % on room air	× /	× ,	× /				
PaO2/FiO2	172.0 (102.1-	104.8 (94.6-	371.7 (350.0-	0.001			
	350.0)	119.0)	422.7)				
>300, n/N (%)	3/10 (30.0%)	0/6 (0.0%)	4/4 (100.0%)	0.007			
200-300, n/N (%)	2/10 (20.0%)	1/6 (16.7%)	0/4 (0.0%)				
100-200, n/N (%)	2/10 (20.0%)	2/6 (33.3%)	0/4 (0.0%)				
$\leq 100, n/N (\%)$	3/10 (30.0%)	3/6 (50.0%)	0/4 (0.0%)				

547 Table 1 Demographics and baseline characteristics of patients with COVID-19

Abbreviations: COVID-19, Coronavirus Disease 2019; FiO2, inspiratory oxygen fraction; IQR,
 interquartile range; PaO2, arterial oxygen tension; SARS-CoV-2, severe acute respiratory syndrome

- 550 coronavirus 2. Data are median (IQR), n (%), or n/N (%), where N is the total number of patients with
- available data. p values comparing severe cases and moderate cases are from χ^2 test, Fisher's exact test,
- 552 or unpaired 2-sided Student's t test.

	Normal	All patients	severe cases	moderate cases	Р
	range	(n=21)	(n=11)	(n=10)	value
White blood cell count, \times 10 ⁹ /L	3.5-9.5	5.7 (4.6-8.3)	8.3 (6.2-10.4)	4.5 (3.9-5.5)	0.00
<4, n (%)		3 (14.3%)	0 (0.0%)	3 (30.0%)	0.01
4-10, n (%)		15 (71.4%)	8 (72.7%)	7 (70.0%)	
≥10, n (%)		3 (14.3%)	3 (27.3%)	0 (0.0%)	
Neutrophil count, $\times 10^{9}/L$	1.8-6.3	4.8 (2.8-6.9)	6.9 (4.9-9.1)	2.7 (2.1-3.7)	0.002
Lymphocyte count, $\times 10^{9}/L$	1.1-3.2	0.9 (0.7-1.1)	0.7 (0.5-0.9)	1.1 (1.0-1.2)	0.04
<0.8, n (%)		9 (42.9%)	8 (72.7%)	1 (10.0%)	0.00
Hemoglobin, g/L	130-175	137.0 (127.0-147.0)	136.0 (125.5-144.5)	139.5 (132.8-146.0)	0.78
Platelet count, $\times 10^{9}/L$	125-350	160.0 (137.0-189.0)	157.0 (134.0-184.5)	175.6 (148.3-194.0)	0.88
<100, n (%)		1 (4.8%)	0 (0.0%)	1 (10.0%)	0.48
Alanine aminotransferase, U/L	≤41	26.0 (16.0-42.0)	42.0 (32.5-50.0)	16.0 (13.3-21.8)	0.00
Aspartate aminotransferase, U/L	≤40	27.0 (21.0-47.0)	47.0 (28.0-74.5)	24.0 (21.5-26.5)	0.014
>40, n (%)		6 (28.6%)	5 (45.5%)	0 (0.0%)	0.03
Albumin, g/L	35.0-52.0	33.7 (29.6-37.4)	29.6 (28.6-33.0)	37.2 (35.8-38.8)	0.013
<32 g/L, n (%)		8 (38.1%)	7 (63.6%)	1 (10.0%)	0.02
Total bilirubin, mmol/L	≤26	8.8 (6.8-10.3)	8.8 (7.9-10.5)	7.8 (6.4-9.5)	0.24
Blood urea nitrogen, mmol/l	3.1-8.0	5.1 (4.1-6.4)	6.1 (5.2-9.1)	4.0 (3.4-4.8)	0.01
Creatinine, µmol/L	59-104	81.0 (67.0-85.0)	82.0 (67.5-91.5)	76.5 (63.3-81.0)	0.21
Creatine kinase, U/L	≤190	73.0 (63.0-287.0)	214.0 (90.0-329.0)	64.0 (57.5-83.5)	0.16
Lactate dehydrogenase, U/L	135-225	336.0 (221.0-537.0)	537.0 (433.5-707.5)	224.0 (200.3-251.8)	0.00
>300 U/L, n (%)		11 (52.4%)	10 (90.9%)	1 (10.0%)	0.00
Prothrombin time, seconds	11.5-14.5	13.7 (13.0-14.5)	14.3 (13.6-14.6)	13.4 (12.8-13.7)	0.15
Activated partial thromboplastin	29.0-42.0	39.4 (33.6-44.5)	33.7 (32.1-38.4)	44.0 (42.6-47.6)	0.00
time, seconds					
D-dimer, µg/mL	< 0.5	0.5 (0.4-1.8)	2.6 (0.6-18.7)	0.3 (0.3-0.4)	0.02
Procalcitonin, ng/mL	0.02-0.05	0.11 (0.05-0.24)	0.18 (0.13-0.81)	0.05 (0.04-0.06)	0.05
<0.1, n/N (%)		7/18 (38.9%)	0/10 (0.0%)	7/8 (87.5%)	0.00
0.1-0.25, n/N (%)		6/18 (33.3%)	6/10 (60.0%)	0/8 (0.0%)	
0.25-0.5, n/N (%)		2/18 (11.1%)	1/10 (10.0%)	1/8 (12.5%)	
≥0.5, n/N (%)		3/18 (16.7%)	3/10 (30.0%)	0/8 (0.0%)	
	<1	108.4 (28.0-139.5)	139.4 (86.9-165.1)	22.0 (14.7-119.4)	0.00
mg/L					
>60, n/N (%)		14/20 (70%)	11/11 (100.0)	3/9 (33.3%)	0.002
Ferritin, µg/L	30-400	1424.6 (337.4-	1598.2 (1424.6-	337.4 (286.2-	0.04
		1780.3)	2036.0)	1275.4)	
>800, n/N (%)		12/19 (63.2%)	9/9 (100.0%)	3/10 (30.0%)	0.00
Bilateral involvement of chest		17/21 (81.0%)	10/11 (90.9%)	7/10 (70.0%)	0.31
computed tomography scan on admission		((

554 Table 2 Laboratory findings and chest CT images of patients with COVID-19

555 Abbreviations: COVID-19, Coronavirus Disease 2019; IQR, interquartile range; SARS-CoV-2, severe 556 acute respiratory syndrome coronavirus 2. Data are median (IQR) or n (%), or n/N (%), where N is the

- 557 total number of patients with available data. p values comparing severe cases and moderate cases are
- 558 from χ^2 , Fisher's exact test, or unpaired 2-sided Student's t test.

560	Table 3 Immunological features of patients with COVID-19)

560 Table 5 Immunologic	All patients severe cases			moderate cases		Normal		
	(n=21)		(n=11)		(n=10)		value	range
Total T lymphocytes (%)	60.5 (54.4-70.	.3)	55.1 (52.2-60.5)		68.8 (64.7-75.2)		0.020	50-84
Total T lymphocytes count, $\times 10^{6}/L$	486.5 (26	57.0-	294.0	(169.3-	640.5	(588.3-	0.011	955-2860
	664.8)		415.3)		789.5)			
decreased, n/N (%)	13/14 (92.9%)		8/8 (100.0%)		5/6 (83.3%)		0.43	
<400, n/N (%)	6/14 (42.9%)		6/8 (75.0%)		0/6 (0.0%)		0.010	
Total B lymphocytes (%)	16.9 (10.8-22.4)		20.2 (17.6-39.5)		10.8 (10.3-12.4)		0.025	5-18
increased, n/N (%)	7/14 (50.0%) 6/8 (75.0%)		0%)	1/6 (16.7%)		0.10		
Total B lymphocytes count, $\times 10^{6}/L$	115.5 (5	57.8-	184.0	(42.8-	115.5	(102.8-	0.35	90-560
	249.3)		273.3)		133.5)			
decreased, n/N (%)	4/14 (28.6%)	4/14 (28.6%) 3/8 (37.5%)		1/6 (16.7%)		0.58		
CD4 ⁺ T cells, (%)	36.7 (32.0-40.	.0)	36.7 (30	36.7 (30.7-37.3)		36.4 (32.0-40.6)		27-51
CD4 ⁺ T cells count, $\times 10^{6}/L$	241.5 (13	35.0-	177.5	(104.0-	381.5	(255.0-	0.018	550-1440
	363.8)		249.8)		451.0)			
decreased, n/N (%)	14/14 (100.0%	6)	8/8 (100).0%)	6/6 (10	0.0%)	NA	
CD8 ⁺ T cells, (%)	22.2 (15.7-26.	.9)	17.4 (14	.7-23.4)	25.2 (22	2.8-34.2)	0.093	15-44
CD8 ⁺ T cells count, \times 10 ⁶ /L	169.5 (8	36.0-	89.0	(61.5-	254.0	(183.3-	0.035	320-1250
	281.5)		130.3)		312.8)			
decreased, n/N (%)	12/14 (85.7%)		7/8 (87.5%)		5/6 (83.3%)		1.00	
<150, n/N (%)	6/14 (42.9%)		6/8 (75.0%)		0/6 (0.0%)		0.010	
NK cells, (%)	14.8 (10.3-21.9)		14.7 (7.5-21.0)		15.1 (11.6-22.8)		0.62	7-40
NK cells count, $\times 10^{6}/L$	89.0 (58.8-20	7.0)	60.5	(27.5-	180.5	(115.0-	0.27	150-1100
			109.0)		228.0)			
decreased, n/N (%)	8/14 (57.1%)		6/8 (75.0%)		2/6 (33.3%)		0.28	
<77, n/N (%)	6/14 (42.9%)		6/8 (75.0%)		0/6 (0.0%)		0.010	
CD28 ⁺ CD4 ⁺ T cells/ CD4 ⁺ T, %	98.3 (96.8-98.	.8)	97.5 (96.8-98.7)		98.6 (97.2-99.0)		1.00	84.11-
								100.00
CD28 ⁺ CD8 ⁺ T cells/ CD8 ⁺ T, %	64.8 (44.6-75.9)		44.6 (37.5-73.1)		70.3 (63.3-76.9)		0.20	48.04-77.14
HLA-DR ⁺ CD8 ⁺ T cells/ CD8 ⁺ T, %	42.3 (30.9-48.2)		46.2 (42.3-48.2)		28.6 (25.4-37.9)		0.19	20.73-60.23
CD45RA ⁺ CD4 ⁺ T cells/ CD4 ⁺ T, %	32.8 (31.7-40.3)		32.8 (31.8-36.4)		36.0 (29.3-40.5)		0.54	29.41-55.41
CD45RO ⁺ CD4 ⁺ T cells/ CD4 ⁺ T, %	67.2 (59.7-68.3)		67.2 (63.6-68.2)		64.0 (59.5-70.7)		0.54	44.44-68.94
Treg, %	4.1 (3.5-4.9)		4.7 (2.6-5.4)		3.9 (3.6-4.3)		0.92	5.36-6.30
CD45RA ⁺ Treg, %	0.8 (0.5-1.1)		0.5 (0.3-0.7)		1.1 (1.0-1.3)		0.020	2.07-4.55
CD45RO ⁺ Treg, %	3.3 (2.4-3.8)		3.8 (1.9-4.9)		2.9 (2.5-3.4)		0.59	1.44-2.76
IFN- γ expressing CD4 ⁺ T cells, %	19.1 (13.0-22.8)		· · · · · · · · · · · · · · · · · · ·		22.8 (18.8-25.4)		0.063	14.54-36.96
IFN-γ expressing CD8 ⁺ T cells, %	50.1 (44.2-53	<i>,</i>		0.2-52.7)	,	7.3-54.1)	0.49	34.93-87.95
IFN-γ expressing NK cells, %	73.3 (65.7-79.	.7)	71.2 (63	8.8-72.9)	79.7 (7)	1.9-81.5)	0.25	61.2-92.65

561 Abbreviations: COVID-19, Coronavirus Disease 2019; IQR, interquartile range; SARS-CoV-2, severe 562 acute respiratory syndrome coronavirus 2. Data are median (IQR) or n/N (%), where N is the total number 563 of patients with available data. p values comparing severe cases and moderate cases are from χ^2 , Fisher's 564 exact test, or unpaired 2-sided Student's t test. 565